Treatment Action Campaign

Pharmaceutical manufacturer Adcock Ingram has issued a recall of certain batches of Adco-Nevirapine and Adco-Zidovudine (what is commonly known as AZT) due to a packaging error. It was discovered by Adcock Ingram that blister packs of Adco-Nevirapine had been packed into nine packs of Adco-Zidovudine. The Nevirapine blister packs were labelled correctly but they had been inserted into AZT boxes.

As a precautionary measure Adcock Ingram is recalling entire batches of the affected anti-retroviral drugs (ARVs). The recalled boxes are: Adco-Nevirapine batch number 1J, expiry date January 2009; and Adco-Zidovudine batch number 1Z, expiry date November 2008. All recalled drugs will be replaced by the correct medication.

TAC has a made a submission to the Department of Health (DoH) and the South African National AIDS Council (SANAC) on the new draft DoH Guidelines on the Management of HIV in Health Facilities (Guidelines). The submission presented yesterday (16 May) by Zackie Achmat at a meeting of SANAC's Techinal Task Team on HIV Treatment, Care and Support. Later this month the submission will also be presented at the SANAC Plenary.

The AIDS Law Project (ALP) has written a memorandum explaining the serious problems with the antiretroviral tender that the state has put out.

Find a public antiretroviral site or private doctor where you can be treated for HIV.

On Wednesday, Sowetan newspaper ran a disturbing story about a man on antiretrovirals who had a particularly bad case of lipodystrophy and grew breasts. This story highlights the need for doctors and nurses to monitor antiretroviral side-effects closely and to take patients concerns about their side-effects seriously. It also shows how important it is for patients to inform their health providers as soon as they experience possible side-effects. 

 Contents

• Tenofovir Campaign details and memo

  Share

  Close

  • Delicious
  • Digg
  • Reddit
  • Facebook
  • Google
  • Yahoo